Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,006 public trials 571 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Completed

High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

NCT02597062

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Regional Health Authority B, Zone 2 Saint John, New Brunswick, Canada
  • QEII Health Sciences Centre Halifax, Nova Scotia, Canada
  • Kingston Health Sciences Centre Kingston, Ontario, Canada
View Trial Details
Completed

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

NCT04196491

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Local Institution - 119 Phoenix, Arizona, United States
  • Local Institution - 110 Los Angeles, California, United States
  • Local Institution - 116 San Francisco, California, United States
  • Local Institution - 106 Denver, Colorado, United States
View all 22 locations
View Trial Details
Completed

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

NCT02755597

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Rocky Mountain Regional VA Medical Center/Eastern Colorado Health Care System /ID# 156524 Aurora, Colorado, United States
  • Univ of Colorado Cancer Center /ID# 149130 Aurora, Colorado, United States
  • Duke Cancer Center /ID# 149099 Durham, North Carolina, United States
  • Gabrail Cancer Center Research /ID# 149098 Canton, Ohio, United States
View all 97 locations
View Trial Details
Completed

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT04445701

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Mayo Clinic Phoenix, Arizona, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • Emory University Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Completed

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

NCT02034110

Conditions
Biliary Tract Diseases, Biliary Tract Neoplasms, Blood Protein Disorders, +35 more
Locations
  • Novartis Investigative Site Little Rock, Arkansas, United States
  • Novartis Investigative Site Santa Monica, California, United States
  • Novartis Investigative Site Bethesda, Maryland, United States
  • Novartis Investigative Site Boston, Massachusetts, United States
View all 41 locations
View Trial Details
Completed

A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide

NCT03215524

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • CrossCancer Institute Edmonton, Alberta, Canada
  • Fraser Valley Cancer Centre Surrey, British Columbia, Canada
  • CancerCare Manitoba Winnipeg, Manitoba, Canada
View Trial Details

Related conditions